Journal List > Transl Clin Pharmacol > v.22(1) > 1082590

Cha, Jeong, Shin, Kim, Yu, Cho, Yoon, and Lim: Genetic Polymorphisms of the Carboxylesterase 1 (CES1) Gene in a Korean Population

Abstract

Human carboxylesterase 1 (CES1) is a serine esterase that hydrolyzes various exogenous compounds. Single nucleotide polymorphisms (SNPs) of CES1 may lead to inter-individual metabolic variability of its substrates. The allele and haplotype frequencies of known SNPs have been demonstrated to vary among ethnic groups. We analyzed genetic variations of CES1 in a Korean population. Direct sequencing of all exons and flanking regions of the CES1 gene was performed on samples obtained from 200 Koreans. We identified 41 SNPs. The most frequent SNPs was −914G>C (frequency: 99.5%), followed by 4256G>A (frequency: 65.8%), −75T>G (frequency: 59.3%). Haplotype analysis using the identified SNPs revealed fifteen haplotypes (≥1% haplotype frequency) in our samples. The most frequent haplotype was Hap1 (frequency: 15.4%). Among the identified 41 SNPs, nine of which are novel variants and 14 SNPs were nonsynonymous variants. Using the functional predictive software PolyPhen-2, the G19V, E221G, and A270S variants were predicted to be most likely damaging to the function and structure of CES1. In-vitro analyses for two of these variants have been previously performed; however, functional evaluation of E221G (11657A>G, rs200707504) still needs to be conducted. Therefore, further studies are warranted to characterize the functional impact of E221G on CES1 activity.

References

1. Kim SR, Nakamura T, Saito Y, Sai K, Nakajima T, Saito H, et al. Twelve novel single nucleotide polymorphisms in the CES2 gene encoding human carboxylesterase 2 (hCE-2). Drug Metab Pharmacokinet. 2003; 18:327–332.
crossref
2. Walter Soria N, Belaus A, Galván C, Ana Pasquali M, Velez P, Del Carmen Montes C, et al. A simple allele-specific polymerase chain reaction method to detect the Gly143Glu polymorphism in the human carboxylesterase 1 gene: importance of genotyping for pharmacogenetic treatment. Genet Test Mol Biomarkers. 2010; 14:749–751.
crossref
3. Suzaki Y, Uemura N, Takada M, Ohyama T, Itohda A, Morimoto T, et al. The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans. Eur J Clin Pharmacol. 2013; 69:21–30.
crossref
4. Staudinger JL1. Xu C, Cui YJ, Klaassen CD. Nuclear receptormediated regulation of carboxylesterase expression and activity. Expert Opin Drug Metab Toxicol. 2010; 6:261–271.
5. Marsh S, Xiao M, Yu J, Ahluwalia R, Minton M, Freimuth RR, ea al. Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics. 2004; 84:661–668.
6. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, La Du BN. Current progress on esterases: from molecular structure to function. Drug Metab Dispos. 2002; 30:488–493.
crossref
7. Redinbo MR, Bencharit S, Potter PM. Human carboxylesterase 1: from drug metabolism to drug discovery. Biochem Soc Trans. 2003; 31:620–624.
crossref
8. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet. 2008; 82:1241–1248.
crossref
9. Zhu HJ, Markowitz JS. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab Dispos. 2009; 37:264–267.
crossref
10. Bruxel EM, Salatino-Oliveira A, Genro JP, Zeni CP, Polanczyk GV, Chazan R, et al. Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate. Pharmacogenomics J. 2013; 13:476–480.
crossref
11. Yamada S, Richardson K, Tang M, Halaschek-Wiener J, Cook VJ, Fitzgerald JM, et al. Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity. Pharmacogenomics J. 2010; 10:524–536.
crossref
12. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010; 7:248–249.
crossref
13. Sunyaev S, Ramensky V, Koch I, Lathe W 3rd, Kondrashov AS, Bork P. Prediction of deleterious human alleles. Hum Mol Genet. 2001; 10:591–597.
crossref
14. Geshi E, Kimura T, Yoshimura M, Suzuki H, Koba S, Sakai T, et al. A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. Hypertens Res. 2005; 28:719–725.
crossref
15. Zhu HJ, Wang X, Gawronski BE, Brinda BJ, Angiolillo DJ, Markowitz JS. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther. 2013; 344:665–672.
crossref
16. Tarkiainen EK, Backman JT, Neuvonen M, Neuvonen PJ, Schwab M, Niemi M. Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Clin Pharmacol Ther. 2012; 92:68–71.
crossref
17. Ding XL, Deng YL, Zhang J, Miao LY. Mutation-sensitive molecular switch method to detect CES1A2 mutation in the Chinese Han and Yao populations. Genet Test Mol Biomarkers. 2011; 15:659–662.
crossref

Table 1.
Primers sequences used for the human CES1 gene analysis
Primer name Region First Long PCR Primer sequence (5'-3') Product size (bp) PCR condition (°C)
CES1 ZtF Promoter-Exon6 TGTCAGAGGCTGCAGCCAGACC 16,532 68
CES1 ZtR GGTTGTTCCACTTACCAGCCATTAGG
CES1 Zt2F Exon7-Exon14 CTTGTGTCTCTCTGGGTCTGCCTAATG 25,188 68
CES1 Zt2R TTGCAAGGCACATGGTTCCCTC
Primer name Region Nested PCR primer sequence (5'-3') Product size (bp) PCR condition (°C)
CES1PF Promoter TGCTCTTTGTGTACAAGCTTTTGTG 755 64
CES1PR CGATCTTAAATTTCATCGAGTCCC
CESE1F Exon1 TCTGACACCGATGGTGTGTGAC 819 65
CESE1R CCAAGTCCAAGTCCTAATATGGAA
CESE2F Exon2 ACTCACTTAGAAAGCGGCAAACT 486 64
CESE2R CACAGCAGGTGCTCAATAAACATG
CESE3F Exon3 CTGGGAGTTCCAAAGGCTCTGGA 425 65
CESE3R CCTTGACCAGGGGGTCCCACAA
CESE4F Exon4 GGTGATGGGAGTGTCCTCCC 501 64
CESE4R AAAGTGCAGTGAGGAGAGTCCG
CESE5F Exon5 TTAAGGGTTCACTGAGAACCCCT 374 64
CESE5R AGGGCCAGTCCTGAATTCAGGTA
CESE6F Exon6 GAGCTGTAGGAAGACTTCCACCTC 313 64
CESE6R GTGTCCAGCCGGAGACGTACCA
CESE7F Exon7 GGGCTTGGGATAGAATGCCACT 239 64
CESE7R TCTGGGACCAAGTTTACAGGGT
CESE8F Exon8 TGATGCGGGAAGAACCTGACA 259 64
CESE8R CAGAAACAAACACGCAGGAGTTA
CESE9F Exon9 AGTCATGGAGACCTACCCCCCTA 411 64
CESE9R AGCTGCCCAGGACTCAGAGTGCA
CESE10F Exon10–11 TCATGCCCTTAAAAGCCCCCATA 659 64
CESE11R TGGGGTTTGTGTCCCTCCCG
CESE12F Exon12 ATGCAGCCCGGAGCGCATCA 337 64
CESE12R CAAGACTGGAACCCAAGTCTCTAAC
CESE13F Exon13–14 AGACTCGCATGTGATGTTGACG 886 64
CESE14R ACCGTTCTGTCTCTGAGGACAAAGT

CES1: carboxylesterase 1

Table 2.
Summary of SNPs and their frequencies in the CES1 gene in a Korean population
CES1: Reference sequence NG_012057.1
SNP (NT change) Location CDS change Amino Acid substitution rs ID Allelic frequency (%)
–1114G>A 5'UTR rs34428341 10.3
–914G>C 5'UTR rs28759040 99.5
–757delC 5'UTR rs57810510 35.3
–722G>A 5'UTR 0.3
–610G>A 5'UTR 0.3
–322T>G 5'UTR 0.3
–161A>G Exon01 (5'UTR) 0.3
–75T>G Exon01 (5'UTR) rs3815583 59.3
–46A>G Exon01 (5'UTR) rs12149373 25.3
–39A>G Exon01 (5'UTR) rs12149371 25.3
–30G>A Exon01 (5'UTR) rs144950224 1.0
–21G>C Exon01 (5'UTR) rs12149322 25.3
–20A>G Exon01 (5'UTR) rs12149370 25.3
–2C>G Exon01 (5'UTR) rs12149368 24.8
11G>C Exon01 11G>C R4P rs111604615 24.8
15C>T Exon01 15C>T A5A 24.8
16T>C Exon01 16T>C F6L rs201577108 24.8
19A>G Exon01 19A>G I7V rs114788146 24.8
34T>G Exon01 34T>G S12A rs12149366 24.8
68A>G Intron01 rs12149359 24.8
73insT Intron01 rs56278207 36.0
4067A>C Intron01 rs3826189 1.5
4085G>T Exon02 56G>T G19V rs3826190 1.5
4256G>A Exon02 227G>A S76N rs2307240 3.3
4363C>T Intron02 rs3848300 65.8
6635A>G Intron02 rs143802684 0.5
11607C>A Exon05 612C>A D204E rs2307227 0.3
11657A>G Exon05 662A>G E221G rs200707504 2.0
11720C>G Intron05 rs2307234 0.3
12630C>T Exon06 747C>T G249G rs202228585 0.5
13423G>T Exon07 808G>T A270S rs115629050 0.8
13447A>G Exon07 832A>G T278A rs200489319 0.3
16094A>G Exon08 907A>G K303E 0.3
19917G>A Intron08 rs3859093 41.3
19923T>C Intron08 rs3859092 41.3
22041T>G Intron09 rs2302722 41.5
22280C>T Intron10 0.3
22351C>T Intron10 rs146930283 17.3
22359C>A Intron10 rs147989545 42.0
22445A>T Exon11 1224A>T T408T 0.3
26503C>A Intron11 0.3
SNPs: single nucleotide polymorphisms, CES1: carboxylesterase. 1.

CDS: coding DNA sequence.

rs ID: reference SNP ID,

Novel variant allele detected in this study.

Table 3.
Summary of haplotypes and their frequencies in the CES1 gene in a Korean population
Haplotype 26503C>A 22445A>T 22359C>A 22351C>T 22280C>T 22041T>G 19923T>C 19917G>A 16094A>G 13447A>G 13423G>T 12630C>T 11720C>G 11657A>G 11607C>A 6635A>G 4363C>T 4256G>A 4085G>T 4067A>C 73insT 73insT 68A>G 34T>G 19A>G 19A>G 16T>C 15C>T 11G>C –2C>G –20A>G –21G>C –30G>A –39A>G –46A>G –75T>G –161A>G –322T>G –610G>A –722G>A –757delC –914G>C –1114G>A Frequency (%)
Hap1 C A C C C T T G A A G C C A C A C G G A A T A T C G C A G G A A T A T G G C C G 15.4
Hap2 C A C C C T T G A A G C C A C A T G G A T G G G C T C G G C G G G G A T G G C C G 12.5
Hap3 C A A C C G C A A A G C C A C A T G G A A T A T C G C A G G A A G A T G G C G 12.3
Hap 4 C A C C C T T G A A G C C A C A C G G A A T A T C G C A G G A A G A T G G C G 7.7
Hap 5 C A A T C G C A A A G C C A C A T G G A A T A T C G C A G G A A G A T G G C G 5.7
Hap 6 C A A T C G C A A A G C C A C A T G G A T T G G G C T C G G C G G G G A T G G C C G 5.2
Hap 7 C A C C C T T G A A G C C A C A C G G A T T A T A T C G C A G G A A T A T G G C C A 5.1
Hap 8 C A C C C T T G A A G C C A C A T G G A A T A T C G C A G G A A G A T G G C G 4.3
Hap 9 C A A C C G C A A A G C C A C A T G G A A T A T C G C A G G A A T A T G G C C G 4.2
Hap 10 C A A T C G C A A A G C C A C A T G G A A T A T C G C A G G A A T A T G G C C G 3.0
Hap 11 C A C C C T T G A A G C C A C A T G G A A T A T C G C A G G A A T A T G G C C G 2.4
Hap 12 C A C C C T T G A A G C C A C A C G G A T T G G G C T C G G C G G G G A T G G C C G 2.4
Hap 13 C A A C C G C A A A G C C A C A T G G A T T G G G C T C G G C G G G G A T G G C C G 1.9
Hap 14 C A A C C G C A A A G C C G C A T G G A A T A T C G C A G G A A G A T G G C G 1.9
Hap 15 C A A T C G C A A A G C C A C A T G G A T T A T A T C G C A G G A A T A T G G C C A 1.6

The data ≥ 1% in haplotype frequency presented.

TOOLS
Similar articles